Lantern Pharma Advances unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers. Lantern, in collaboration with academic research partners, has advanced the development, synthesis, and preclinical proof-of-concept of a novel, highly potent, cryptophycin-based ADC. The cryptophycin ADC has shown picomolar potency in a wide range of solid tumors tested in preclinical development and is being further evaluated for clinical potential in six solid tumor indications.

The company has leveraged RADR®?, a proprietary AI platform for oncology drug development, for target selection and molecular payload characterization in ADCs, and a unique, controlled conjugation approach for maximizing drug-to-antibody ratios while controlling for non-specific conjugation. The proprietary AI and machine learning (ML) RADR®? platform leverages over 60 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development.

By harnessing the power of AI and with input from world-class scientific advisors and collaborators, have accelerated the development of company growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, company newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in approximately 2-3 years and at approximately $1.0-2.0 million per program.